Editorial
Let’s come together to fight with pancreatic cancer
Chinese Clinical Oncology
2023;
12
(1)
:1
.
(28 February 2023)
Original Article
Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues
Chinese Clinical Oncology
2023;
12
(1)
:2
.
(28 February 2023)
Bilateral mastectomy associated with higher breast cancer mortality among patients with estrogen receptor positive progesterone receptor negative localized breast cancer
Chinese Clinical Oncology
2023;
12
(1)
:3
.
(28 February 2023)
Review Article
Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review
Chinese Clinical Oncology
2023;
12
(1)
:4
.
(28 February 2023)
Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma
Chinese Clinical Oncology
2023;
12
(1)
:5
.
(28 February 2023)
Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and recommendations for current practice
Chinese Clinical Oncology
2023;
12
(1)
:6
.
(28 February 2023)
2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review
Chinese Clinical Oncology
2023;
12
(1)
:7
.
(28 February 2023)
Editorial Commentary
Management of the neck in nasopharyngeal carcinoma—time for a radical change?
Chinese Clinical Oncology
2023;
12
(1)
:8
.
(28 February 2023)
Interviews with Outstanding Guest Editors1
Interview with Prof. Uei Pua—discussion with an interventional oncologist
Chinese Clinical Oncology
2023;
12
(1)
:9
.
(28 February 2023)
Disclosure:
1. The series “Interviews with Outstanding Guest Editors” was commissioned by the editorial office, Chinese Clinical Oncology without any funding or sponsorship.
